NCT00545194

Brief Summary

The aim of this study is to compare two different preparation

Trial Health

30
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Timeline
Completed

Started Jan 2002

Typical duration for phase_3

Geographic Reach
1 country

1 active site

Status
withdrawn

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2002

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

October 1, 2004

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

October 1, 2004

Completed
3 years until next milestone

First Submitted

Initial submission to the registry

October 16, 2007

Completed
1 day until next milestone

First Posted

Study publicly available on registry

October 17, 2007

Completed
Last Updated

September 4, 2025

Status Verified

October 1, 2007

Enrollment Period

2.8 years

First QC Date

October 16, 2007

Last Update Submit

August 28, 2025

Conditions

Keywords

Prostaglandin E2Intravaginal gelBishop scoreInduction of laborrandomized trialVaginal insert

Outcome Measures

Primary Outcomes (1)

  • Percentage of vaginal deliveries within the 48 hours after cervical ripening

    48 hours

Secondary Outcomes (10)

  • Proportion of total vaginal deliveries

    48 hours

  • Vaginal deliveries at 12 hours, 24 hours and 36 hours

    48 hours

  • Number of hyperkinesia with or without fetal heart rate monitoring abnormalities

    48 hours

  • Number of hypertonia with or without fetal heart rate monitoring abnormalities

    48 hours

  • Apgar score at 5 min less or equal 7

    48 hours

  • +5 more secondary outcomes

Study Arms (2)

A

ACTIVE COMPARATOR

sustained release preparation of prostaglandin E2

Drug: Prostaglandin E2

B

ACTIVE COMPARATOR

short-acting (instant-released) preparation of prostaglandin E2

Drug: Prostaglandin E2

Interventions

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • singleton pregnancy
  • cephalic presentation
  • gestation of more than 37 Weeks confirmed by ultrasound
  • Bishop score less than 7
  • Informed consent

You may not qualify if:

  • previous cesarean section (scarred uterus)
  • polyhydramnios
  • multiple pregnancy
  • fetal malformation

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Olympe de Gouges Women Health Centre, Bretonneau University Hospital

Tours, 37044, France

Location

Related Publications (3)

  • Lyrenas S, Clason I, Ulmsten U. In vivo controlled release of PGE2 from a vaginal insert (0.8 mm, 10 mg) during induction of labour. BJOG. 2001 Feb;108(2):169-78. doi: 10.1111/j.1471-0528.2001.00039.x.

    PMID: 11236117BACKGROUND
  • Strobelt N, Meregalli V, Ratti M, Mariani S, Zani G, Morana S. Randomized study on removable PGE2 vaginal insert versus PGE2 cervical gel for cervical priming and labor induction in low-Bishop-score pregnancy. Acta Obstet Gynecol Scand. 2006;85(3):302-5. doi: 10.1080/00016340500523685.

    PMID: 16553177BACKGROUND
  • El-Shawarby SA, Connell RJ. Induction of labour at term with vaginal prostaglandins preparations: a randomised controlled trial of Prostin vs Propess. J Obstet Gynaecol. 2006 Oct;26(7):627-30. doi: 10.1080/01443610600903362.

    PMID: 17071427BACKGROUND

MeSH Terms

Interventions

Dinoprostone

Intervention Hierarchy (Ancestors)

Prostaglandins EProstaglandinsEicosanoidsFatty Acids, UnsaturatedFatty AcidsLipidsAutacoidsInflammation MediatorsBiological Factors

Study Officials

  • Franck Perrotin, MD-PhD

    Tours Universiity Hospital

    PRINCIPAL INVESTIGATOR
0

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER GOV
Responsible Party
SPONSOR

Study Record Dates

First Submitted

October 16, 2007

First Posted

October 17, 2007

Study Start

January 1, 2002

Primary Completion

October 1, 2004

Study Completion

October 1, 2004

Last Updated

September 4, 2025

Record last verified: 2007-10

Locations